Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing pantoprazole, a proton pump inhibitor (PPI), and amoxicillin and clarithromycin, antibiotics. It is designed for the eradication of *Helicobacter pylori* (*H. pylori*).
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
The standard regimen is **one Sompraz HP pack twice daily for 7 to 14 days**. Each pack typically contains pantoprazole 40 mg, amoxicillin 500 mg, and clarithromycin 500 mg, to be taken in the morning and evening. Specific pack contents may vary, and the full regimen duration should be followed as prescribed.
## Pediatric Dosing
Dosing for pediatric patients is not well-established for this combination product and should be determined by a specialist based on patient weight and clinical assessment. Standard *H. pylori* eradication regimens in children often involve weight-based dosing of individual agents.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment for the individual components at standard doses, however, caution is advised in severe renal impairment for clarithromycin. Consult individual drug monographs for specific guidance.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Severe renal impairment (for clarithromycin).
* Congenital QT prolongation, history of torsades de pointes, hypokalemia, hypomagnesemia (for clarithromycin).
* Concurrent use with cisapride, pimozide, or other drugs metabolized by CYP3A4 with a narrow therapeutic index.
* History of penicillin allergy.
## Adverse Effects
**Common:** Diarrhea, nausea, headache, abdominal pain, dizziness, rash.
**Less Common/Serious:** *Clostridioides difficile*-associated diarrhea, Stevens-Johnson syndrome, toxic epidermal necrolysis, hypersensitivity reactions, QT prolongation, hepatic dysfunction, renal impairment, dysgeusia (altered taste).
**Amoxicillin-related:** Rash, urticaria, anaphylaxis, interstitial nephritis.
**Clarithromycin-related:** QT prolongation, hepatotoxicity, pancreatitis.
**Pantoprazole-related:** Fundic gland polyps (long-term use), hypomagnesemia, *Clostridioides difficile*-associated diarrhea, bone fracture (long-term use).
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Clarithromycin is a potent CYP3A4 inhibitor. Concomitant use with CYP3A4 substrates (e.g., carbamazepine, cyclosporine, digoxin, theophylline, warfarin, statins) may increase their serum concentrations and risk of toxicity.
* **Drugs Affecting Gastric pH:** PPIs can affect the absorption of other drugs.
* **Penicillin-allergic patients:** Avoid amoxicillin.
* **Anticoagulants:** Monitor INR closely if co-administered with warfarin.
* **QT-prolonging agents:** Use with caution due to clarithromycin's potential to prolong the QT interval.
* **Probenecid:** May decrease the excretion of amoxicillin.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for development of *Clostridioides difficile*-associated diarrhea.
* Monitor renal and hepatic function, especially in patients with pre-existing impairment.
* For patients on warfarin, monitor INR regularly.
* Consider electrolyte monitoring (especially magnesium) with prolonged pantoprazole use.
* Evaluate for signs of *H. pylori* eradication via stool antigen testing or urea breath test after completion of therapy.
## Clinical Pearls
* This combination product is designed for ease of administration but requires adherence to the full prescribed duration.
* It is crucial to counsel patients on the importance of completing the entire course of antibiotics, even if symptoms improve.
* Patients with a history of penicillin allergy should not receive amoxicillin. Alternative *H. pylori* eradication regimens should be considered.
* Acid suppression with pantoprazole is essential for the efficacy of the antibiotics in eradicating *H. pylori*.
* Advise patients to report any severe or persistent diarrhea, rash, or signs of allergic reaction immediately.
***
**Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before initiating treatment, as drug information can change. This summary does not replace professional medical judgment.
